Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
Rhea-AI Summary
Galmed Pharmaceuticals (NASDAQ: GLMD) signed a definitive agreement to acquire Colospan, creating a GI-focused medtech and biopharmaceutical platform targeting a $6 billion colorectal surgery market.
Colospan’s CG-100 intraluminal bypass device holds FDA Breakthrough Device status, is CE marked, in a U.S. pivotal IDE trial, and planned for EU launch in H2 2026. Deal consideration totals $4.5 million plus a planned $6 million EU launch investment, with closing expected in Q2 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Acquisition of CG-100 device with FDA Breakthrough Device Designation and CE (MDR) mark
- Planned $6 million investment to launch CG-100 in Europe in H2 2026
- Transforms Galmed into a diversified GI-focused medtech and biopharmaceutical platform
- Transaction consideration of $4.5 million for a commercial-stage colorectal surgery device company
Negative
- Equity portion of $2.0 million in Galmed shares may dilute existing shareholders
- Additional $6 million launch investment increases near-term cash outflows
- CG-100 still under U.S. IDE, with FDA approval and commercialization timing uncertain
- Transaction closing depends on customary conditions, adding execution risk to Q2 2026 timeline
News Market Reaction – GLMD
On the day this news was published, GLMD declined 12.36%, reflecting a significant negative market reaction. Argus tracked a peak move of +35.0% during that session. Argus tracked a trough of -47.9% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $648K from the company's valuation, bringing the market cap to $4.59M at that time. Trading volume was exceptionally heavy at 135.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Cardiac fibrosis data | Positive | -5.0% | Preclinical Aramchol Meglumine combo cut cardiac fibrotic burden about fourfold. |
| May 14 | PK study results | Positive | +10.6% | Phase 1 PK data showed ~5-fold higher Aramchol bioavailability for AM 400mg. |
| May 06 | Cardiac platform deal | Positive | +6.4% | Collaboration to build human-centered cardiac fibrosis organoid platform for Aramchol. |
| Apr 14 | Brain cancer research | Positive | -6.7% | Collaboration to test brain-penetrant Aramchol in p53-deficient metastatic brain cancers. |
| Apr 09 | CNS formulation advance | Positive | +26.1% | New brain-penetrant Aramchol formulation targeting synucleinopathies with in vitro data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent R&D updates on Aramchol have often produced sharp but inconsistent moves, with both strong rallies and selloffs following generally positive scientific news.
Over the last few months, Galmed has focused on expanding Aramchol into cardiometabolic, neurological, and oncology indications. Key updates included a brain-penetrant formulation with a 26.14% move on Apr 9, cardiac fibrosis collaboration news with mixed reactions, and pharmacokinetic data on Aramchol meglumine that drove a 10.62% gain on May 14. Today’s acquisition of Colospan shifts emphasis toward a GI-focused medtech and biopharma platform, adding a commercial-stage device alongside the existing Aramchol pipeline.
Regulatory & Risk Context
Key Terms
fda breakthrough device designation regulatory
ide regulatory
ce marked regulatory
medical device regulation ("mdr") regulatory
intraluminal bypass device medical
anastomotic leak medical
diverting stoma medical
pivotal trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Transaction will add FDA Breakthrough Device-Designated technology with active
U.S . pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. - Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and
Israel . Galmed contemplates an investment of$6 million Europe with an initial focus onGermany ,Austria andSwitzerland . - Upon closing, Colospan will become a wholly owned subsidiary of Galmed, repositioning it as a GI-focused medtech and biopharmaceutical platform. Transaction approved by both boards; expected to close Q2 2026.
RAMAT GAN,
Upon closing, Colospan will become a wholly owned subsidiary of Galmed. The acquisition is designed to accelerate Galmed's strategy to create a diversified, GI-focused medtech and biopharmaceutical platform, combining Galmed's established public company infrastructure, cash reserves, and GI clinical expertise with Colospan's proprietary device technology and active
Colospan's flagship product, the CG-100 intraluminal bypass device, is a minimally invasive alternative designed to protect the anastomosis, minimize patient burden, and reduce the need for a diverting stoma - a temporary abdominal opening that redirects waste to an external bag while healing occurs. The CG-100 is CE marked under the MDR and is currently under investigational use only (under IDE) in the
"CG-100 is a category leader having an FDA Breakthrough Device Designation and a CE (MDR) European regulatory status ready for commercialization. The expected acquisition of Colospan is a defining moment for Galmed and we believe is the type of asset that moves the needle," said Allen Baharaff, Co-founder and Chief Executive Officer of Galmed Pharmaceuticals. "The acquisition of Colospan aligns perfectly with our long-term growth strategy. We are bringing more than 25 years of clinical execution capabilities together with our public company experience and resources to accelerate the CG-100 pivotal study to obtain FDA regulatory approval. We believe our shared vision will allow us to scale Colospan's technologies faster, and substantially accelerate our path to success."
Boaz Assaf, Founder and Chief Executive Officer of Colospan commented: "Colorectal cancer is the third most commonly diagnosed cancer in both men and women with ~ 1.9M diagnosed cases worldwide annually. Colorectal resection is the most common medical treatment for colorectal cancer and is performed on majority of patients worldwide to remove the tumor. Anastomotic leaks, a failure of the surgical connection, occur in up to
Under the terms of the definitive agreement, Colospan shareholders and SAFE holders will receive
Roth Capital Partners, LLC served as financial advisor to Galmed. Meitar Law Offices serves as legal counsel to Galmed, and Matry Meiri Wacht & Co. serves as legal counsel to Colospan.
ABOUT GALMED PHARMACEUTICALS LTD.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is an
ABOUT COLOSPAN LTD.
Colospan Ltd. is a commercial-stage medical device company headquartered in Kfar Saba, Israel. Its flagship product, CG-100, is an intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas, offering a less invasive alternative to standard
surgical practice. CG-100 was granted FDA Breakthrough Device Designation, is CE marked under the EU Medical Device Regulation, and is approved for investigational use in the United States under an FDA approved IDE. The device is not approved for commercial use in the US. For more information, visit www.colospan.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to anticipated or expected events, activities, trends, or results as of the date they are made, including statements regarding the expected benefits of the acquisition and transaction timing. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
Factors that could cause differences include, but are not limited to the possibility that the transaction does not close, including due to failure of closing conditions; Galmed's inability to recognize the anticipated benefits of the acquisition of Colospan; expectations with respect to future performance and growth of Colospan; Galmed and Colospan's ability to execute their business plans and strategy and to receive regulatory approvals; potential litigation involving the parties; changes in domestic and foreign business, market, financial, political and legal conditions; market adoption and pricing barriers; intellectual property enforcement or infringement claims; manufacturing and supply chain constraints; intense industry competition; the ability to maintain listing on the Nasdaq Capital Market; geopolitical events, including the security situation in Israel; regulatory changes; access to additional financing; and other risks and uncertainties indicated from time to time in filings with the SEC by Galmed Additional risks relating to Colospan's product and its strategy are detailed in a report on Form 6-K filed by Galmed with the SEC on June 8, 2026 and risks associated with Galmed are detailed in Galmed's Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 under the heading "Risk Factors." Galmed undertakes no obligation to publicly update or revise any forward-looking statements to reflect new information, change in expectations, subsequent events, or otherwise, except as required by law.
Logo: https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-acquire-colospan-to-create-a-gi-focused-platform-targeting-a-6-billion-market-302793948.html
SOURCE Galmed Pharmaceuticals Ltd.